Nereus Pharmaceuticals - Top 20 VC deals of 2007

Company: Nereus Pharmaceuticals
Based: San Diego, CA
Amount: $45M
Round: Fourth
Investors: Advent International, Alta Partners, Astellas Venture Capital , BankInvest, Cheng Xin Technology Development Corp., Eminent Venture Capital Corp., F. Hoffmann - La Roche, Ltd., Forward Ventures, GIMV, HBM BioVentures, InterWest Partners, Novartis Venture Fund, Pacific Venture Group, Red Abbey Venture Partners, Societe Generale - Private Equity Activity, Undisclosed Investor, Undisclosed Venture Firm

Scoop: The money will be used to complete Phase I and begin Phase II clinical trials for Nereus' two drug candidates. The first compound, NPI-2358, is being evaluated for the treatment of solid tumors and lymphomas in Phase I clinical trials. NPI-2358 belongs to a class of compounds that disrupts the intrinsic tumor blood flow, which leads to tumor cell death. It's is one of 200 analogues that were produced after finding activity and novel chemistry from a marine fungal extract.

More News:
Nereus gains $45M in D-2 round for cancer drugs. Report

Nereus Pharmaceuticals - Top 20 VC deals of 2007
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.